Advertisement

Prophylaxe und Therapie venöser Thromboembolien bei Patienten mit Malignomen

  • C. Faul
  • H.-P. Lipp
  • C. Bokemeyer
Chapter
  • 21 Downloads

Zusammenfassung

Gerinnungsstörungen sind bei Patienten mit Malignomen häufig. Bis zu 15% aller Tumorpatienten entwickeln im Verlauf ihrer Erkrankung thromboembo-lische Komplikationen. Vom Tumorleiden unabhängige Risikofaktoren können die Inzidenz weiter erhöhen (s. folgende Übersicht). Das Risiko postoperativer tiefer Beinvenenthrombosen ist z. B. für Krebspatienten nach allgemeinchirurgischen Eingriffen mit 36% nahezu doppelt so hoch wie für Patienten ohne Malignom (20%).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur zu 13

  1. Bern MM, Lokich JJ, Wallach SR et al. (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112: 423–428PubMedGoogle Scholar
  2. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB (1995) The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 74: 1055–1058PubMedGoogle Scholar
  3. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar W (1996) Low-molecular weight heparin vs. warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 20: 521–526PubMedCrossRefGoogle Scholar
  4. Fraschini G, Jadeja J, Lawson M et al. (1987) Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients. J Clin Oncol 5: 672–678PubMedGoogle Scholar
  5. Harenberg J, Leber G, Dempfle CE et al. (1989) Long term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulants. Nouv Rev Fr Hematol 31: 363–369PubMedGoogle Scholar
  6. Hirsh J (1991) Heparin. N Engl J Med 324: 1565–1574CrossRefGoogle Scholar
  7. Hull RD, Raskob GE, Pineo GF et al. (1992) Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 326: 975–982PubMedCrossRefGoogle Scholar
  8. Koopman MM, Prandoni P, Piovella F et al. (1996) Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. The Tasman Study Group. N Engl J Med 334: 682–687PubMedCrossRefGoogle Scholar
  9. Levine M, Gent M, Hirsh J, Leclerc J et al. (1996) A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334: 677–681PubMedCrossRefGoogle Scholar
  10. Levine M, Hirsh J (1990) The diagnosis and treatment of thrombosis in the cancer patient. Semin Oncol 17: 160–171PubMedGoogle Scholar
  11. Levine M, Hirsh J, Gent M et al.(1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343: 886–889PubMedCrossRefGoogle Scholar
  12. Levine MN, Gent M, Hirsh J et al. (1988) The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318: 404–407PubMedCrossRefGoogle Scholar
  13. Levine MN, Hirsh J, Gent A et al. (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154: 49–56PubMedCrossRefGoogle Scholar
  14. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D (1994) Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 72: 186–190PubMedGoogle Scholar
  15. Lipp HP (1997) Heparine, Heparinoide und Hirudoide bei Lungenembolie und Thrombosen. PZ 142: 1455–1462Google Scholar
  16. Lipp HP (1997) Perorale Antikoagulanzien: bewährt in der Thromboseprophylaxe. PZ 142: 1551–1559Google Scholar
  17. Monreal M, Lafoz E, Olive A, Rio L del, Vedia C (1994) Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 71: 7–11PubMedGoogle Scholar
  18. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ (1996) Cancer and venous thromboembolism. Am Heart J 132: 850–855PubMedCrossRefGoogle Scholar
  19. Pini M, Aiello S, Manotti C et al. (1994) Low-molecular weight heparin vs. warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 72: 191–197PubMedGoogle Scholar
  20. Prandoni P, Lensing AWA, Büller HR et al. (1992) Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327: 1128–1133PubMedCrossRefGoogle Scholar
  21. Raschke RA, Gollihare B, Peirce JC (1996) The effectiveness of implementing the weight-based Heparin nomogram as a practice guideline. Arch Int Med 156: 1645–1649CrossRefGoogle Scholar
  22. Schiff D, DeAngelis LM (1994) Therapy of venous thromboembolism in patients with brain metastases. Cancer 73: 493–498PubMedCrossRefGoogle Scholar
  23. Schwarz RE, Marrero AM, Conlon KC, Burt M (1996) Inferior vena cava filters in cancer patients: indications and outcome. J Clin Oncol 14: 652–657PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • C. Faul
  • H.-P. Lipp
  • C. Bokemeyer

There are no affiliations available

Personalised recommendations